CytoReason's machine-learning algorithms extract information from multi-omic measurements to improve indication prioritization and highlight new treatment targets.
Diversigen will act as a central lab for generating and incorporating microbiome data into the Crohn's & Colitis Foundation's IBD Plexus platform.
In Science this week: gene variant linked to inflammatory bowel disease, and more.
New research suggests that some risky and protective variants in the LRRK2 gene have shared genetic effects in Crohn's disease and Parkinson's disease.
The agreement, with Genetic Analysis of Oslo, involves technology to detect gut dysbiosis and investment for additional tests.
A team has identified disease loci for Crohn's and ulcerative colitis using fine mapping alongside high-density genotyping.
The researchers plan to profile patients with both Adaptive Biotechnologies' ImmunoSeq platform and 10x Genomics' single-cell immune repertoire profiling technology.
The firm's recent funding round will support its CLIA-certified laboratory that opened last year and the launch of its first RNA-based diagnostic test.
The Dutch firm expects its product to be the first commercial test on the market to diagnose IBD by analyzing a patient's gut microbiome.
The project aims to elucidate markers of response and non-response to current treatment regimens, and to identify new therapies.
According to New Scientist, GEDmatch changed its terms and conditions over the weekend to opt its users out of law enforcement searches.
The Atlantic looks into time spent pursuing gene leads generated through candidate gene studies.
A twin study uncovers evidence that genes may influence whether someone gets a dog, Martha Stewart reports.
In PNAS this week: Cdx2 cells can help regenerate heart tissue in mice following a heart attack, PIWI-interacting small RNA levels in human cancer, and more.